Study of maraviroc for active myositis
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system clinical trials.
This trial tests whether a drug called maraviroc, which is usually used for HIV, can also reduce inflammation in people with myositis. It is for patients whose myositis is still active despite taking multiple standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 79 years old.
- You need a confirmed diagnosis of myositis (a disease causing muscle inflammation).
- Your myositis must be active, meaning muscle weakness and other signs like high muscle enzymes, despite current treatment with steroids and at least two other immune-suppressing drugs.
- You cannot be pregnant or breastfeeding.
- You must not have a history of cancer (excluding some skin cancers).
- You must be able to take the study drug, maraviroc.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
This trial tests an investigational drug called telitacicept for people with inflammatory myopathy (muscle inflammation). It may help reduce muscle weakness and other symptoms when standard treatments haven't worked well enough.
This study follows people with inflammatory myositis over time to learn more about the condition. If you join, you may receive closer monitoring and contribute to research that could improve future treatments.
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
This trial tests a new drug called nerandomilast in people with active inflammatory muscle disease (myositis) that is not well controlled with current treatments. It aims to see if the drug can improve muscle strength and overall disease activity.
This trial tests a new treatment called CABA-201, which uses your own immune cells modified to attack the overactive cells causing myositis. It is for people with active disease that hasn't improved enough with standard therapies.
Hear when a new Myositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.